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Abstract
Background: The endogenous cannabinoid system is involved in the control of pain. However, little is known as to the
integrity of the cannabinoid system in human pain syndromes. Here we investigate the expression of the cannabinoid
receptor 1 (CB1) in human Achilles tendons from healthy volunteers and from patients with Achilles tendinosis.
Methodology: Cannabinoid CB1 receptor immunoreactivity (CB1IR) was evaluated in formalin-fixed biopsies from
individuals suffering from painful Achilles tendinosis in comparison with healthy human Achilles tendons.
Principal Findings: CB1IR was seen as a granular pattern in the tenocytes. CB1IR was also observed in the blood vessel wall
and in the perineurium of the nerve. Quantification of the immunoreactivity in tenocytes showed an increase of CB1
receptor expression in tendinosis tissue compared to control tissue.
Conclusion: Expression of cannabinoid receptor 1 is increased in human Achilles tendinosis suggesting that the
cannabinoid system may be dysregulated in this disorder.
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Introduction
It has been known for many years that cannabinoids are effective
for the relief of a variety of types of pain [1], and activation of
cannabinoid (CB) receptors by compounds such as nabilone have
been shown to have clinicalutilityin a varietyof painstates, including
cancer pain, neuropathic pain, and fibromyalgia [2–4]. Data from
studies on experimental animals indicate that the antinociceptive
effects of cannabinoids are not only centrally mediated, but that
spinal and peripheral CB receptors are involved [5].
The antinociceptive effects of exogenous CBreceptor agonists raise
the possibility that the endocannabinoid system is dysfunctional in
pain states. There is evidence of this in animal models of pain [6–10],
but little is known about the situation in human pain. To our
knowledge, the only data so far reported are findings of an increased
plasma concentration of the endocannabinoid anandamide in
patients with complex regional pain syndrome compared to age-
and sex-matched controls [11], a negative correlation between CB1
receptor expression inpancreatic nerves and strong pain symptoms in
patients with pancreatic cancer [12], and a positive correlation of
suburothelial CB1-immunoreactive nerve fibers with the pain score in
painful bladder syndrome [13]. There is thus a need for more data on
the status of the endocannabinoid system in human pain states.
The Achilles tendon is the strongest tendon in the body and the
understanding of pain in this tendon is of utmost importance. When
there is chronic pain and impaired function in the Achilles tendon,
the condition is referred to as tendinopathy. Clinically, the tendon
thickens and becomes tender. Biopsies show changes in the
appearance of the tenocytes, hypercellularity and neovascularization
and eventually degenerative features [14–19]. When there are
structural changes, the condition is commonly called tendinosis [20].
Achilles tendinosis most often occurs in the mid-portion of the
tendon. Imaging with ultrasonography or magnetic resonance
imaging (MRI) can be used to verify tendon abnormalities in the
painful area [18,21]. The pain in chronic Achilles tendinosis
remains an enigma. However, injections and mini-surgery to areas
of neovascularization outside the tendonhave been shown toreduce
the pain seen in chronic Achilles tendinosis [22,23]. Although
several molecular candidates have been identified and proposed as
mediators of the pain in Achilles tendinosis [24], information on the
cannabinoidsystemislacking.Inconsequence,wehaveinvestigated
the expression of CB1 receptors in human Achilles tendons and
whether there is a change in expression in Achilles tendinosis.
Methods
Ethics Statement
The Committee of Ethics at the Faculty of Medicine, Umea ˚
University and the Regional Ethical Review Board in Umea ˚
approved the project (04-157 M). Participants gave verbal consent
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statement and receiving a verbal summary of the project. The
Review Board approved the verbal consent procedure. When
approval from patients had been obtained, specimens were
collected and taken care of for the research and documentation
was made. This form of approval and documentation is in
accordance with paragraph 16 and 17 of the Ethical review act in
Sweden. All procedures followed the principles of the Declaration
of Helsinki.
Individuals
This investigation included tissue samples from 24 individuals:
11 males and 13 females (mean age: 48 years, range 21–70 years;
male mean age: 44 years, range 28–70 years; female mean age: 52
years, range 21–68 years). The samples were from a group of
patients suffering from Achilles tendinosis and from healthy
controls. The Achilles tendinosis group (n=17) were suffering from
chronic painful mid-portion Achilles tendinosis. This group
consisted of 8 males and 9 females (mean age: 51, range 28–70
years; male mean age: 45 years, range 28–70; female mean age: 57
years, range 47–68 years). Tendinosis was verified by ultrasonog-
raphy. The control group consisted of individuals (n=7) with no
history of pain symptoms from their Achilles tendons (mean age:
41 years, range 21–47 years; 3 males, mean age 41 years, range
39–46 years; 4 females, mean age: 41, range 21–47 years).
Ultrasonography showed normal tendons. All patients were
otherwise healthy and non-smokers.
Sampling, fixation and sectioning
In the tendinosis group, biopsies were taken during surgical
treatment. Under local anaesthesia (4–5 ml pilocaine hydrochlo-
ride, 10 mg/ml; AstraZeneca, So ¨derta ¨lje, Sweden), tendon tissue
(macroscopically abnormal) was taken from the ventral part of the
Achilles tendon through a longitudinal incision lateral to the
tendon mid-portion. The biopsies contained tendon tissue proper,
and to varying degrees, outer parts of the tendon (paratendinous
connective tissue). The tissue samples were approximately 2 mm
wide and 1–5 mm long and were taken from different depths of
the tendon. From the control group, samples of the same size were
collected from the dorsal part of the tendon using a longitudinal
plain incision under local anaesthesia. The dorsal part of the
tendon was chosen for ethical and practical reasons.
Directly after the surgical procedures, the samples were fixed
overnight at 4uC in a solution of 4% formaldehyde in 0.1 M
phosphate buffer, pH 7.0, followed by thorough washing in
Tyrode’s solution containing 10% sucrose, at 4uC overnight. The
samples were then mounted on thin cardboard in OCT
embedding medium (Miles Laboratories, Naperville, IL,USA)
and frozen at 280uC until sectioning.
For the immunofluorescence and morphologic investigations,
series of 7 mm thick sections from both groups of samples were cut
using a cryostat (Leica Microsystem CM3050S, Heidelberg,
Germany). The sections were mounted on slides, pre-coated with
crome-alun gelatine, and the sections were then dried and
thereafter processed for immunohistochemistry. Staining with
hematoxylin-eosin was carried out to delineate tissue morphology.
Reference tissues (human colonic and rat dorsal root ganglion
tissue), available at the laboratory, were examined in parallel.
They had been fixed and further processed in the same way as the
tendon samples.
Immunofluorescence
Sections were initially treated with acid potassium permanga-
nate for 2 min to enhance the visualization of specific immuno-
fluorescence reaction sites [25]. The sections were then rinsed in
0.01 M phosphate-buffered saline (PBS) pH 7.4 containing 0.1%
sodium azide as preservative, for 365 min. After these procedures,
incubation for 20 min in a 1% solution of detergent Triton X-100
(Kebo Lab, Stockholm, Sweden) in 0.01 M PBS, and rinsing for
365 min in PBS were performed. The sections were then
incubated in 5% normal swine serum in PBS supplemented with
0.1% bovine serum albumin (BSA) for 15 min in a humid
environment in room temperature. Thereafter followed incubation
with the primary antibody, diluted in PBS with BSA. The
incubation was performed in a humid environment and proceeded
for 60 min at 37uC. The sections were then washed in PBS for
365 min prior to another incubation in normal swine serum for
15 min in a humid environment in room temperature, followed by
incubation with the secondary antibody. This antibody corre-
sponded to tetramethylrhodamine isothiocyanate (TRITC)- con-
jugated swine antirabbit igG (DakoCytomation, Glostrup, Den-
mark). The secondary antibody was diluted in PBS with BSA
(1:40). Incubation proceeded for 30 min at 37uC in a humid
environment. A Zeiss Axioskop II microscope equipped with an
Olympus DP70 digital camera was used for examination of the
sections.
For semiquantitative determination of the intensity of CB1
receptor immunoreactivity in the control and Achilles tendinosis
tendons, two of the researchers (EB, SF), who were blinded to the
clinical data for the patients, independently scored the CB1
expression in the sections under the fluorescence microscope. The
tenocytes were scored for immunoreactive intensity (0–3 where 0 is
absent and 3 is high), and the average value was taken. This
method of scoring has previously been used in other published
studies by co-author Forsgren [26,27], including studies using the
immunofluorescence technique on tendon tissue [28]. For the CB1
receptor immunoreactivity scores returned by the two investiga-
tors, an intraclass coefficient analysis using a two-way mixed effects
model for the 24 scores gave a Cronbach’s alpha reliability
coefficient of 0.79, suggesting that the inter-rater reliability is
acceptable.
Antibodies and control stainings
The antibodies used were against CB1 and PGP9.5. Both are
rabbit antibodies. The CB1 antibody (rabbit polyclonal; ab23703;
Abcam, Cambridge, UK) had been raised against the C-terminal
amino acid 461–472 of human CB1. Concentrations used were
1:20–1:100. For the experiments comparing immunoreactivity for
controls and tendinosis patients, a dilution of 1:50 was used. The
antibody to PGP9.5 (rabbit polyclonal; code 7863-0504; Biogen-
esis, Poole, UK), was used at a dilution of 1:100, and had been
raised against native brain PGP9.5.
For control purposes, sections were processed with PBS/BSA
instead of primary antibodies. To confirm further the specificity,
the primary CB1 antibody was pre-absorbed overnight at 4uC with
its immunogenic peptide (20–100 mg/ml; ab50542; Abcam,
Cambridge, UK) prior to incubation on the sections. The
PGP9.5 antibody has been used in numerous studies in the
laboratory [29,30] and in numerous studies by others for the
purpose of demarcating nerve fibres.
Statistics
The two-tailed Mann-Whitney test was undertaken using the
Statistical package built into the GraphPad Prism 5 computer
programme for the Macintosh (GraphPad Software Inc., San
Diego, CA, USA). The intraclass coefficient analysis was
conducted using IBM SPSS Statistics 19 for the Macintosh (IBM
Inc., Somers, NY, USA).
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CB1 receptor immunoreactivity (CB1IR) in the normal
Achilles tendon and in reference tissue
Figure 1 shows the CB1IR for normal Achilles tendons, in which
the tendon cells (tenocytes) show the characteristic elongated
appearance [18,19,31] and, for comparative purposes, that for
human colon and the rat dorsal root ganglion. For all three cases,
CB1IR was seen. For the tendons, CB1IR was observed for the
tenocytes (Fig. 1A) and in blood vessel walls (not shown). The
reactions in the tenocytes showed a punctuate appearance along
the length of the cells (Fig. 1A). Preabsorption with the
corresponding peptide eliminated the immunostainings (Fig. 1B),
as did control stainings when the primary antibody was omitted
(data not shown). As positive controls, CB1IR was investigated in
the human colon and the dorsal root ganglia. For the human
colon, distinct specific reactions were seen for cells of the mucosa
and submucosa and in cells in the epithelial layer (Fig. 1C), in
agreement with the literature [32]. Distinct specific reactions were
also seen for neuronal perikarya of the dorsal root ganglion. The
reactions occurred as granular intracellular reactions (Fig. 1E).
The presence of intracellular CB1IR can also be seen in the
literature [33]. For both human colon and the rat dorsal root
ganglia, preabsorption with the corresponding peptide eliminated
the immunostainings (Fig. 1D and F).
CB1IR in Achilles tendinosis
The CB1IR pattern in tenocytes of samples obtained from
patients with Achilles tendinosis is shown in low magnification in
(Fig. 2A–B), where Fig. 2B shows that preincubation with the
antigen prevents all the immunoreactive staining. At a higher
magnification, a granular pattern of immunoreactivity was seen for
the tenocytes. That was especially the situation for rounded/
swollen tenocytes and tenocytes with a wavy appearance. These
abnormally-formed tenocytes are a characteristic of Achilles
tendinosis [16,19]. The tenocyte reactions appeared overall to
be the strongest in the tendinosis specimens.
CB1IR in blood vessel walls and nerve structures
CB1IR was also observed in blood vessel walls and in the
perineurium of nerves in the samples, especially in the tendinosis
samples. For the blood vessel walls (confirmed by htx-eosin
staining Fig. 3A), CB1IR was in the form of fine pointed reactions
(Fig. 3B). They were seen for small vessels but not for large vessels.
Preabsorption with the immunising peptide confirmed specificity
of the antibody (data not shown).
Nerve fascicles were demarcated via showing a distinct PGP9.5
immunoreaction (Fig. 3C). CB1IR was detected in the perineuri-
um of the nerve fascicles. No such reactions were, on the other
hand, detected within the interior of the nerve fascicles (Fig. 3D).
The nerve related immunoreactions were abolished following
preabsorption with the antigen peptide (data not shown).
Semiquantitative comparison of tenocyte CB1IR in
controls and patients with Achilles tendinosis
A semiquantitative analysis of the reaction intensities for the
tenocytes was performed. CB1 was scored in tenocytes from a total
of 24 patients either suffering from chronic Achilles tendinosis or
having clinically pain-free Achilles tendons. Difference in CB1
expression between groups was statistically significant (p,0.05,
Mann-Whitney U test) (Fig. 4). It should be noted that the control
patient with the highest CB1IR was presumably asymptomatic at
the time of biopsy, but that the tendon showed pathology
consistent with Achilles tendinopathy, thus questioning whether
this sample is a true control. Exclusion of this sample from the data
set increased the level of significance to p,0.005.
Discussion
In this study we demonstrate, for the first time, that CB1IR is
detectable within the tenocytes of the human Achilles tendon.
Immunoreactions were also seen in the walls of small blood vessels
walls and in the perineurium of nerves. On the other hand, whilst
CB1IR was detectable in the neuronal perikarya of the rat spinal
ganglion, CB1IR was not detectable in the nerves of tendon tissue.
The antibody used for these studies, raised against the C-
terminal amino acid 461–472 sequence of human CB1, has been
found previously to produce the appropriate staining in brain
samples, but not to stain samples from CB1 knockout mice [34,35].
The antibody has been used, by us and others, to investigate CB1
receptor expression pattern in human bladder [36] and fallopian
tube [37], and in colorectal and prostate cancer biopsies [34,35].
We noted that immunoreactivity was present for non-neuronal
cells and that it was not limited to the cell plasma membranes, but
that intracellular reactions were also seen. Similarly we noted in
the present study that the CB1IR was detectable intracellularly in
the neuronal cell perikarya and in the cells of the mucosa/
submucosa and the epithelial cells of the colon. Although at first
sight this may seem strange for a G-protein coupled receptor, it is
known that the majority of the endogenous CB1 receptors do not
Figure 1. Immunofluorescence for CB1 in normal Achilles
tendon and in reference tissue. Panels show sections processed
for CB1 (a,c,e) and with CB1 antibody preabsorbed with CB1 antigen
(b,d,f). Immunoreactions are shown in the elongated tenocytes in (a)
but not in (b). Arrows indicate tenocytes. Immunoreactions are also
seen in cells of the mucosa and submucosa (arrows) and the epithelial
layer (arrowheads) of human colon in (c) but not in (d), and in cell
bodies of a rat dorsal root ganglion in (e) but not in (f) (arrows).
Asterisks in similar region in (c) and (d). Original magnification 640.
doi:10.1371/journal.pone.0024731.g001
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presence of intracellularly located CB1 receptors in immunohis-
tochemical and western blot experiments [35,38–41]. Further-
more, there is evidence in neuroblastoma cells that at least some of
the intracellular CB1 receptors are functionally active and couple
to the extracellular signal-regulated kinase-signalling pathway
[38]. A recent study shows that anandamide, an endogenous CB1
receptor agonist, can activate intracellular CB1 receptors and
provide evidence that these are functional [42].
The function of the CB1 receptors in the tenocytes can at
present only be a matter of speculation, but the present data add to
the literature indicating that these cells are not simply inert cells
but express receptors for a variety of signalling molecules that
presumably affect their function [19,43–46]. Interestingly, teno-
cytes in the human Achilles tendon have been found to show
expression of transporters or enzymes favouring that these cells
can produce nerve signal signal substances, such as acetylcholine
[44], glutamate [46] and catecholamines [19]. They were also
found to show expression of mRNA for substance P [43]. They
show in addition expression of receptors for neurotransmitters
[19,43–44]. These features were clearly obvious in tendinosis
tendons and most clearly so for tenocytes showing abnormal
appearances, whilst such features were very vague or not detected
at all in normally appearing tenocytes. This means that tenocytes
can develop ‘‘neuronal-like’’ characteristics in terms of expressions
of nerve signal substances and expressions of receptors for these. It
is also a well-known fact that there are no nerve fibres within the
Figure 2. Immunofluorescence for CB1 in Achilles tendinosis.
Panels show sections of Achilles tendinosis tendons processed for
demonstration of CB1 (a,c,d) and of CB1 after preabsorption with the
immunogenic peptide (b). Numerous tenocytes are seen in low
magnification in (a) and (b) (arrows at tenocytes). They show specific
immunoreactions in (a) but not in (b). In panel c and d in which the
tenocytes are shown in high magnification, punctuate immunoreac-
tions in tenocytes are shown (arrows). Original magnification620 (a,b),
663 (c,d).
doi:10.1371/journal.pone.0024731.g002
Figure 3. Immunofluorescence for CB1 in blood vessel and
nerve fasicle. Panels show sections of Achilles tendinosis tissue
showing a small blood vessel (a,b) and a part of a nerve fascicle (c,d)
stained with htx-eosin (a), processed for CB1IR (b,d), and for PGP9.5 (c).
Immunoreactions (arrows) are seen in the blood vessel wall (b) and in
the perineurium of the nerve fascicle (arrows) (d). Original magnification
620 (a),640 (c,d),663 (b). Asterisks in similar region in (a) and (b) and
in the perineurium in (c) and (d).
doi:10.1371/journal.pone.0024731.g003
Figure 4. CB1IR scores for biopsy samples from controls and
patients with Achilles tendinopathy. Shown is a box and whiskers
plot of CB1 immunoreactivity in pain-free Achilles tendons (controls,
n=7) vs. tendons from patients with Achilles tendinopathy (n=17).
*p=,0.05, two-tailed Mann-Whitney U test. Values are mean of the
scoring made by the two investigators.
doi:10.1371/journal.pone.0024731.g004
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present in the outer part of the tendon (the peritendinous tissue)
and to a very small extent in the connective tissue septa [30].
These findings may suggest that biochemical mediators, such as
nerve signal substances, produced in the tendon tissue, can be
involved in the aetiology and pathogenesis of chronic tendon pain
in tendinosis [47]. A ‘‘biochemical model’’ of this type, involving
other locally produced signal substances, has also previously been
considered [48]. This means that the pain is not only structural in
origin. To what extent such a model is related to what we see here,
i.e. an up-regulation of CB1IR for tenocytes in tendinosis tendons,
the CB1 immunoreactions being especially obvious for tenocytes
with an abnormal morphology, remains to be further explained. In
any case, our observations show that the cannabinoid receptor
system in the Achilles tendon is mainly related to the tendon cells
and not being confined to the nerve fibres.
In the present study, the robust and reliable semiquantitative
determination method used, also found that there was a higher
CB1 receptor expression level in the tenocytes of patients with
Achilles tendinosis than in the control group, suggesting that the
cannabinoid system may be dysregulated in this disorder. It is
possible that the increased expression may be an adaptive
consequence to a loss of local endocannabinoid signalling, and it
would clearly be of interest to investigate local endocannabinoid
levels in microdialysis studies from this patient group.
An alternative explanation is that the increased CB1 receptor
expression is due to changes in its cellular regulation produced by
the local environment in the disorder. There is evidence in the
literature that inflammatory processes can affect expression of CB1
receptors in some cases, but not others: Izzo et al. [49] for example
demonstrated that croton oil-induced intestinal inflammation
resulted in a three-fold increase in CB1 receptor expression in
the jejunum. In contrast, cystitis produced by intravesical
administration of acrolein did not affect bladder CB1 investigation
at the time points chosen [50]. CB1 and CB2 receptors can be
regulated by both pro- and anti-inflammatory cytokines [51], and
a good example of this is the ability of interleukin-4 (IL-4) to
increase CB1 receptor expression in lymphocytes by a Stat-6
mediated pathway [52,53]. Tenocytes in primary culture express
interleukin-4 (IL-4) receptors [45]. However, inflammation
presumably occurs only at the beginning of tendinosis, and there
are no signs of inflammation at the time when the biopsy samples
used here were taken, so that if the increased expression found in
the present study emanates from the early inflammation, it would
have to be a very long-lasting effect, or due to the residual
presence of a factor long after resolution of the inflammation. This
does not, of course, rule out the possibility that other factors, i.e.
not associated with inflammation, are involved in the regulation of
CB1 receptor expression in the tendons. Experiments in both
patient tissue and animal models of Achilles tendinopathy [54] are
clearly needed to explore further the mechanisms behind the
increased CB1 receptor expression in Achilles tendinosis.
In conclusion, the present study has demonstrated the
expression of CB1 receptors in Achilles tenocytes, thereby adding
to the growing list of non-neuronal cell types that express these
receptors, and that their expression is increased in tendinosis.
These data underline the need for further studies on endocanna-
binoid signalling in human pain conditions.
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